NYSE Arca · AEON
AEON Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AEON: Nov 13, 2026
AEON Biopharma, Inc. Class A Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.39.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.07 | $-0.13 | 2 |
| Dec 2026 | $-0.09 | $-0.08 | $-0.09 | 2 |
| Mar 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · Oct 23, 6:21 PM EDTAEON Biopharma, Inc. Details ABP-450 Biosimilar Strategy and Plans Q4’26 IND SubmissionPriveterra Acquisition Corp. II, operating as AEON Biopharma, Inc., disclosed an updated corporate presentation on October 23, 2026, regarding the development of ABP-450 as a potential clinically substitutable therapeutic alternative to BOTOX. During Q3 2026, the company received
- Fintel · Oct 2, 9:06 AM EDTAEON Biopharma Consensus Price Target Raised by 16.39% to $1.81The average one-year price target for AEON Biopharma (NYSEAM:AEON) has been revised to $1.81 / share, up 16.39% from the prior estimate of $1.56 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation o
- RTTNews · Sep 30, 2:49 PM EDTBiotech Stocks Surge – NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON(RTTNews) – Several biotech and healthcare stocks moved sharply higher on September 30, 2026, following company-specific developments including clinical data, financing activity and regulatory updates.
- RTTNews · Sep 30, 8:37 AM EDTAEON Gains FDA Feedback On ABP-450 Biosimilar Pathway(RTTNews) – On Wednesday, AEON Biopharma (AEON) said feedback from a Type 2b meeting with the U.S. Food and Drug Administration (FDA) provided further clarity on the development pathway for ABP-450 as a biosimilar to BOTOX.
- RTTNews · Sep 30, 8:30 AM EDTAEON Clarifies ABP-450 Biosimilar Development Plan(RTTNews) – Wednesday, AEON Biopharma (AEON) said FDA feedback from a Type 2b meeting provided clarity on the development pathway for ABP-450 as a biosimilar to BOTOX.
- RTTNews · Sep 10, 2:49 PM EDT5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus(RTTNews) – Several biotech stocks were in focus Thursday, including Tenon Medical following the full repayment of its senior convertible promissory notes; AEON Biopharma after positive forced degradation study results for ABP-450; Silexion Therapeutics ahead of several September
- RTTNews · Sep 10, 6:03 AM EDTAEON Reports Comparable Forced Degradation Results For ABP-450 In Pilot Study; Stock Up(RTTNews) – AEON Biopharma, Inc. (AEON) announced positive results from a pilot forced degradation study comparing ABP-450 with BOTOX (onabotulinumtoxinA), adding to the analytical evidence supporting the products' comparability.
- RTTNews · Aug 19, 8:54 AM EDTAEON Reports Expanded Structural Data Supporting Molecular Similarity Of ABP-450 To BOTOX(RTTNews) – AEON Biopharma, Inc. (AEON) announced expanded structural analysis supporting the molecular similarity of ABP-450 to BOTOX, as the company advances ABP-450 as a biosimilar to BOTOX for therapeutic indications in the U.S.
- RTTNews · Aug 4, 5:39 AM EDTAEON Biopharma Regains NYSE Listing Compliance(RTTNews) – AEON Biopharma, Inc. (AEON) announced that it has received written notice from NYSE confirming that the company has regained compliance with NYSE American's continued listing standards related to stockholders' equity.
- RTTNews · Jul 14, 10:38 AM EDTAEON Biopharma Prices Upsized Public Offering With Potential Gross Proceeds Of Up To $43.3 Mln(RTTNews) – AEON Biopharma, Inc. (AEON), a biopharmaceutical company, on Tuesday announced the pricing of an upsized underwritten public offering expected to generate approximately $13.75 million in immediate gross proceeds, with the potential for total gross proceeds of up to $4
- RTTNews · Mar 31, 6:06 AM EDTAEON Posts Net Loss In FY25; Plans To Request BPD Type 2b Meeting For ABP-450 In 2026; Stock Down(RTTNews) – AEON Biopharma, Inc. (AEON), a biopharmaceutical company, announced financial results for the full year 2025, reflecting a net loss compared to a profit in the prior year. In addition, the firm provided a business update.
- RTTNews · Mar 27, 9:42 AM EDTWeekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease, Lyme disease, kidney disease, ovarian cancer and Type 1 Diabetes.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AEON Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.